| 摘要 |
Disclosed is the use of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid or a pharmaceutically-acceptable salt thereof for treating serotonin (5-hydroxytryptamide, 5-HT) receptor-mediated conditions, wherein the medicament antagonizes a 5-HT2A receptor in an animal suffering from the condition, and wherein the condition is selected from a group consisting of: platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attacks, stable angina, unstable angina, thrombotic stroke, a secondary ischemic event, atrial fibrillation, thrombosis, restenosis, asthma, and a pathology associated with diabetes. |
